CVET - CVET STOCK NEWS

Covetrus (CVET) reported strong Q1 2021 results with net sales of $1.10 billion, a 3% increase compared to Q1 2020. Adjusted EBITDA rose 19% to $57 million, driven by healthy demand in North America and an improvement in operational efficiency. Net loss was narrower at $16 million, or $0.11 per diluted share, compared to a loss of $33 million in the prior year. Despite challenges in Europe, particularly in the U.K. and Germany, the company affirmed full-year adjusted EBITDA guidance of $245-$255 million, a $5 million increase from previous projections.

Covetrus (NASDAQ: CVET) announced the appointment of Pete Perron as president of strategic partnerships. With over 25 years of experience in the pharmaceutical and healthcare sectors, Perron will focus on strengthening supplier relationships, global procurement, and managing North American membership organizations. His role aims to leverage Covetrus's capabilities to improve outcomes for veterinary partners and manufacturer stakeholders. CEO Ben Wolin expressed enthusiasm for Perron's leadership, noting his potential to create value for customers and stakeholders.

Covetrus (NASDAQ:CVET) will release its first quarter 2021 results post-market on May 6, 2021. A conference call is scheduled for 4:30 PM ET with CEO Ben Wolin and CFO Matthew Foulston to discuss the results. Investors can access the live webcast on their Investor Relations page. A replay will be available for two weeks after the call. Covetrus focuses on animal health technology and services, aiming to enhance veterinary practice efficiency and outcomes, serving over 100,000 customers globally.

Covetrus (NASDAQ: CVET) has appointed Stacey M.M. Shirra as the new vice president of global talent management, a role aimed at accelerating the company’s three-year growth strategy. Shirra will oversee the global talent strategy, focusing on employee development and fostering an innovative culture. She brings valuable experience from her tenure at Apple, where she managed executive development programs. This strategic addition is expected to enhance Covetrus' organizational health and performance management, aligning with the company's commitment to its workforce as critical to future success.

Covetrus (Nasdaq: CVET) reported strong financial results for Q4 and full-year 2020, with net sales reaching $1.1 billion and $4.3 billion, marking increases of 11% and 9%, respectively. The company achieved non-GAAP adjusted EBITDA of $56 million for Q4, up from $47 million, and $226 million for the year, up 13%. Despite a net loss of $4 million in Q4, compared to $37 million the previous year, Covetrus improved profitability significantly. Cash and equivalents stood at $290 million with $590 million in available liquidity. The 2021 guidance for adjusted EBITDA is set at $240-$250 million.

Covetrus (NASDAQ: CVET) has appointed Dr. Link Welborn as its Chief Veterinary Officer (CVO) for North America. Dr. Welborn, a respected veterinarian and owner of multiple AAHA-accredited hospitals, will advocate for veterinary practices and improve business outcomes. His focus will be on enhancing connections between Covetrus and the veterinary community amid evolving industry dynamics. Dr. Welborn brings expertise in practice management and has received several prestigious awards, indicating his commitment and influence in the veterinary field.

Covetrus (NASDAQ: CVET) will announce its fourth quarter and full-year 2020 results on March 1, 2021. A conference call is scheduled for 8:30 AM ET, featuring CEO Benjamin Wolin and CFO Matthew Foulston, who will discuss the financial outcomes. Interested parties can access the call via the Investor Relations page on Covetrus' website. An archived version of the call will also be available. Covetrus focuses on animal-health technology and services, serving over 100,000 customers globally.

Covetrus (NASDAQ: CVET) has appointed Deborah Sharkey as the chief consumer officer, a new role aimed at enhancing the relationship between veterinarians and pet owners. Sharkey, who has extensive experience in e-commerce, will oversee marketing, product, and strategy for Covetrus' consumer group. The company emphasizes the importance of convenience for pet owners, aligning with its mission to empower veterinarians for better animal health outcomes. Covetrus will also participate in the upcoming Animal Health Innovation Europe forum.

Covetrus (NASDAQ: CVET) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021. President and CEO Benjamin Wolin, along with CFO Matthew Foulston, will present virtually at 8:20 a.m. ET and take questions from analysts. A live audio webcast will be accessible on the Company’s Investor website, with a replay available for 90 days afterward.

Founded in Portland, Maine, Covetrus is a leading animal-health technology and services company serving over 100,000 customers globally, focusing on enhancing veterinary practice outcomes.